Scar-Pipeline Review, H2 2016

Scar-Pipeline Review, H2 2016

  • Products Id :- GMDHC8406IDB
  • |
  • Pages: 90
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Scar-Pipeline Review, H2 2016


Global Markets Direct's, 'Scar-Pipeline Review, H2 2016', provides an overview of the Scar pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Scar, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Scar and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Scar

The report reviews pipeline therapeutics for Scar by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Scar therapeutics and enlists all their major and minor projects

The report assesses Scar therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Scar

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Scar

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Scar pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Scar Overview 9

Therapeutics Development 10

Pipeline Products for Scar-Overview 10

Pipeline Products for Scar-Comparative Analysis 11

Scar-Therapeutics under Development by Companies 12

Scar-Therapeutics under Investigation by Universities/Institutes 14

Scar-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Scar-Products under Development by Companies 18

Scar-Products under Investigation by Universities/Institutes 19

Scar-Companies Involved in Therapeutics Development 20

3M Drug Delivery Systems 20

Albireo AB 21

Altacor Limited 22

Beech Tree Labs, Inc. 23

Clanotech AB 24

Escape Therapeutics, Inc. 25

FirstString Research, Inc. 26

LegoChem Biosciences, Inc 27

Moerae Matrix, Inc. 28

Promore Pharma 29

RXi Pharmaceuticals Corporation 30

VBS Pharmaceuticals 31

Scar-Therapeutics Assessment 32

Assessment by Monotherapy Products 32

Assessment by Target 33

Assessment by Mechanism of Action 35

Assessment by Route of Administration 37

Assessment by Molecule Type 39

Drug Profiles 41

A-3914-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

A-5425-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

BTL-slo-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

CLT-28643-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

decorin-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Drug to Agonize Beta 2 Receptor for Wound Scars-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

FibroStem-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

FS-2-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Granexin-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

ICX-RHY-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

LCB-030110-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

MG-53-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

MMI-0100-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Monoclonal Antibody to Inhibit LRG1 for AMD, Diabetic Retinopathy, Oncology and Scar-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

nefopam hydrochloride-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

OLX-101-Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Polysaccharide for Wounds and Scars-Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

PXL-01-Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Recombinant Protein for Immunology, Dermatology, Oncology and Musculoskeletal Disorders-Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

Recombinant Protein for Scar-Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

RXI-109-Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

S-34240-Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology-Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

tranilast-Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

Scar-Dormant Projects 76

Scar-Discontinued Products 77

Scar-Product Development Milestones 78

Featured News & Press Releases 78

Aug 18, 2016: ScarX announces approval for trial of first clinically-promising scar reduction cream 78

Apr 28, 2016: RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model 79

Apr 25, 2016: RXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference 80

Apr 19, 2016: RXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate RXI-109 80

Mar 31, 2016: Rxi Pharmaceuticals Strengthens Intellectual Property Portfolio for Dermal Indications 81

Mar 28, 2016: RXi Pharmaceuticals to Present at the Oligonucleotide Therapeutics and Delivery Conference 82

Feb 16, 2016: Accel-Rx/BDC make second portfolio investment in ScarX Therapeutics 82

Oct 12, 2015: RXi Pharmaceuticals to Present at Premier Scientific Plastic Surgery Meeting 83

Oct 05, 2015: RXi Pharmaceuticals Bolsters Protection for its Novel Self-Delivering RNAi Platform with Notice of Allowance from USPTO 84

Sep 29, 2015: RXi Pharmaceuticals to Present at Dawson James Securities Growth Stock Conference 84

Sep 28, 2015: RXi Pharmaceuticals Granted Patent in China for Lead Clinical Candidate RXI-109 85

Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 85

Mar 23, 2015: RXi Pharmaceuticals Reports Positive Advancements in its Dermatology Programs at the Occasion of the 73rd Annual Meeting of the American Academy of Dermatology 85

Dec 17, 2014: RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 87

Sep 29, 2014: RXi Pharmaceuticals to Present at the 13th Annual BIO Investor Forum 88

Appendix 89

Methodology 89

Coverage 89

Secondary Research 89

Primary Research 89

Expert Panel Validation 89

Contact Us 89

Disclaimer 90

List of Figures

Number of Products under Development for Scar, H2 2016 10

Number of Products under Development for Scar-Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy Products, H2 2016 32

Number of Products by Top 10 Targets, H2 2016 33

Number of Products by Stage and Top 10 Targets, H2 2016 33

Number of Products by Top 10 Mechanism of Actions, H2 2016 35

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 35

Number of Products by Routes of Administration, H2 2016 37

Number of Products by Stage and Routes of Administration, H2 2016 37

Number of Products by Molecule Types, H2 2016 39

Number of Products by Stage and Top 10 Molecule Types, H2 2016 39

List of Tables

Number of Products under Development for Scar, H2 2016 10

Number of Products under Development for Scar-Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Development, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Investigation by Universities/Institutes, H2 2016 19

Scar-Pipeline by 3M Drug Delivery Systems, H2 2016 20

Scar-Pipeline by Albireo AB, H2 2016 21

Scar-Pipeline by Altacor Limited, H2 2016 22

Scar-Pipeline by Beech Tree Labs, Inc., H2 2016 23

Scar-Pipeline by Clanotech AB, H2 2016 24

Scar-Pipeline by Escape Therapeutics, Inc., H2 2016 25

Scar-Pipeline by FirstString Research, Inc., H2 2016 26

Scar-Pipeline by LegoChem Biosciences, Inc, H2 2016 27

Scar-Pipeline by Moerae Matrix, Inc., H2 2016 28

Scar-Pipeline by Promore Pharma, H2 2016 29

Scar-Pipeline by RXi Pharmaceuticals Corporation, H2 2016 30

Scar-Pipeline by VBS Pharmaceuticals, H2 2016 31

Assessment by Monotherapy Products, H2 2016 32

Number of Products by Stage and Target, H2 2016 34

Number of Products by Stage and Mechanism of Action, H2 2016 36

Number of Products by Stage and Route of Administration, H2 2016 38

Number of Products by Stage and Molecule Type, H2 2016 40

Scar-Dormant Projects, H2 2016 76

Scar-Discontinued Products, H2 2016 77

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

3M Drug Delivery Systems

Albireo AB

Altacor Limited

Beech Tree Labs, Inc.

Clanotech AB

Escape Therapeutics, Inc.

FirstString Research, Inc.

LegoChem Biosciences, Inc

Moerae Matrix, Inc.

Promore Pharma

RXi Pharmaceuticals Corporation

VBS Pharmaceuticals

Scar Therapeutic Products under Development, Key Players in Scar Therapeutics, Scar Pipeline Overview, Scar Pipeline, Scar Pipeline Assessment

select a license

Single User License
USD 2000 INR 136600
Site License
USD 4000 INR 273200
Corporate User License
USD 6000 INR 409800



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]